GILD vs ABBV Stock Comparison: AI Score, Valuation, Performance and Upside
Gilead and AbbVie are both large-cap biopharma income investments with dominant franchises (Biktarvy HIV and Skyrizi/Rinvoq immunology respectively) and substantial dividends. They operate in completely different therapeutic areas with different pipeline risks and revenue profiles. Gilead's antiviral dominance is more concentrated but highly durable; AbbVie is successfully replacing Humira with its successor immunology drugs while Botox diversifies into consumer healthcare.
GILD vs ABBV is a comparison between the antiviral market leader with oncology diversification (Gilead) and the post-Humira immunology giant with aesthetics diversification (AbbVie) — both pay significant dividends from large franchise revenues and are investing in pipeline diversification to sustain long-term earnings.
GILD holds the edge across 3 of 5 key metrics in this comparison. GILD leads on both 1-year return (+32.12%) and forward P/E quality (14.73x vs 15.79x for ABBV), a relatively favorable combination of momentum and valuation. ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +8.05% for GILD and +7.85% for ABBV.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- prefer an antiviral-dominant biopharma with Biktarvy HIV franchise providing extremely durable recurring revenue
- value Trodelvy ADC and CAR-T oncology pipeline as diversification into high-growth cancer treatment markets
- want dividend income from HIV antiviral cash flows with potential upside from MASH and oncology pipeline catalysts
- are comfortable with long-acting injectable HIV competition and Trodelvy label expansion risk as key clinical milestones
- prefer AbbVie's successful Humira transition to Skyrizi and Rinvoq as two of the most successful immunology drug launches ever
- value Botox aesthetics as consumer healthcare revenue diversification that is partially uncorrelated with drug patent cliffs
- want a large-cap biopharma income investment with 3%+ dividend yield supported by immunology franchise cash flows
- are comfortable with Humira biosimilar erosion continuing and Skyrizi/Rinvoq facing competition from next-generation immunology drugs
| Metric | GILD | ABBV |
|---|---|---|
| AI scorei | 42.9 | 53.2 |
| AI ranki | #899 | #353 |
| Latest closei | $150.11 | $263.96 |
| 1M returni | +1.70% | -0.76% |
| 6M returni | +6.38% | +27.99% |
| 1Y returni | +32.12% | +18.91% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GILD | ABBV |
|---|---|---|
| 1Y ago | $13.21K (+32.1%) started 2025-09-18 | $11.89K (+18.9%) started 2025-09-18 |
| 5Y ago | $28.21K (+182.1%) started 2021-09-20 | $33.47K (+234.7%) started 2021-09-20 |
| 10Y ago | $37.67K (+276.7%) started 2016-09-19 | $95.09K (+850.9%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | GILD | ABBV |
|---|---|---|
| Market capi | $180.64B | $454.36B |
| Trailing P/Ei | 17.74 | 72.43 |
| Forward P/Ei | 14.73 | 15.79 |
| Price/Salesi | 4.87 | 5.85 |
| EV/Revenuei | 6.63 | 8.06 |
| Analyst targeti | $157.41 | $277.31 |
| Target upsidei | +8.05% | +7.85% |
| Metric | GILD | ABBV |
|---|---|---|
| Revenue growthi | 10.20% | 10.20% |
| Earnings growthi | 54.80% | 290.40% |
| EPS growthi | +54.80% | +290.40% |
| FCF margini | +32.07% | +26.20% |
| Operating margini | 33.68% | 40.03% |
| Profit margini | -10.64% | 9.80% |
| ROIC proxyi | -20.68% | 6225.00% |
| Return on equityi | -20.68% | 6225.00% |
| Dividend yieldi | 2.20% | 2.69% |
| Payout ratioi | 43.40% | 190.40% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.34 | 0.28 |
| Debt/equityi | 223.47 | 4789.60 |
| Current ratioi | 1.26 | 0.81 |
| Quick ratioi | 0.90 | 0.49 |
Over the past year, GILD and ABBV have moved weakly in the same direction (correlation of 0.39), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | GILD | ABBV |
|---|---|---|---|
| 1Y | Growthi | +32.12% | +18.91% |
| CAGRi | +32.14% | +18.92% | |
| Volatilityi | 26.54% | 26.43% | |
| Sharpe ratioi | 1.02 | 0.62 | |
| Sortino ratioi | 1.61 | 0.94 | |
| Max drawdowni | 22.03% | 19.23% | |
| Current drawdowni | 3.65% | 0.76% | |
| Avg drawdowni | 8.03% | 7.66% | |
| Ulcer Indexi | 10.23% | 9.00% | |
| Max daily dropi | 3.72% | 5.20% | |
| Max wkly dropi | 5.98% | 8.49% | |
| 5Y | Growthi | +143.25% | +186.61% |
| CAGRi | +19.48% | +23.47% | |
| Volatilityi | 24.79% | 23.37% | |
| Sharpe ratioi | 0.66 | 0.83 | |
| Sortino ratioi | 1.02 | 1.16 | |
| Max drawdowni | 26.59% | 21.92% | |
| Current drawdowni | 3.65% | 0.76% | |
| Avg drawdowni | 9.00% | 8.02% | |
| Ulcer Indexi | 10.96% | 9.97% | |
| Max daily dropi | 10.15% | 12.57% | |
| Max wkly dropi | 9.78% | 17.30% | |
| 10Y | Growthi | +160.48% | +508.23% |
| CAGRi | +10.05% | +19.79% | |
| Volatilityi | 25.59% | 26.02% | |
| Sharpe ratioi | 0.33 | 0.65 | |
| Sortino ratioi | 0.49 | 0.91 | |
| Max drawdowni | 30.47% | 45.09% | |
| Current drawdowni | 3.65% | 0.76% | |
| Avg drawdowni | 13.26% | 11.54% | |
| Ulcer Indexi | 15.16% | 15.57% | |
| Max daily dropi | 10.15% | 16.25% | |
| Max wkly dropi | 12.29% | 19.39% |
| Category | GILD | ABBV |
|---|---|---|
| Company | Gilead Sciences, Inc. | AbbVie Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Gilead Sciences is a biopharmaceutical company focused on antiviral medications, oncology, and inflammation. Its antiviral franchise includes Biktarvy (HIV), Veklury (remdesivir for COVID), and hepatitis C treatments. Gilead's oncology portfolio (Trodelvy, Yescarta CAR-T) is a growing revenue driver as the company diversifies beyond antivirals. Gilead also acquired CymaBay (liver disease) and has MASH pipeline assets. The company pays a substantial dividend supported by its antiviral cash flows. | AbbVie is one of the world's largest biopharmaceutical companies, historically dependent on Humira (adalimumab) which lost US market exclusivity in early 2023. Its immunology successors Skyrizi (risankizumab, IL-23) and Rinvoq (upadacitinib, JAK1) are growing rapidly across multiple immune-mediated diseases and collectively generate $15B+ in annual revenue. AbbVie's aesthetics business (Botox via Allergan acquisition) provides consumer-facing revenue diversification. A substantial dividend (3%+ yield) is supported by immunology cash flows. |
| Investor focus | Investors track Biktarvy HIV revenue sustainability, Trodelvy oncology label expansion, CAR-T (Yescarta/Tecartus) revenue growth, MASH pipeline progress, and dividend sustainability from antiviral cash flows. | Investors track Skyrizi and Rinvoq combined revenue growth across psoriasis, IBD, atopic dermatitis, and rheumatoid arthritis, Botox aesthetic revenue in consumer healthcare, Humira biosimilar market share erosion pace, and dividend sustainability. |
- Biktarvy is the most prescribed HIV regimen globally, generating $12B+ annually with high patient adherence and switching costs
- Trodelvy ADC (antibody-drug conjugate) is FDA-approved in multiple cancer types with additional label expansion ongoing
- Strong balance sheet and antiviral cash flows support both dividend payments and M&A to diversify the oncology pipeline
- Skyrizi and Rinvoq are two of the most successful immunology drug launches in history, collectively growing faster than Humira's peak revenue
- Allergan aesthetics (Botox, Juvederm) provides consumer healthcare diversification that is more recession-resistant than pure biotech revenue
- Deep immunology expertise and JAK/IL-23 mechanisms cover a broad range of immune diseases, enabling label expansions across many conditions
- HIV market faces long-acting injectable competition from ViiV Healthcare (Cabenuva/Cabotegravir) that could erode Biktarvy's share
- Oncology pipeline milestones (Trodelvy in lung, bladder, other cancers) are critical to sustaining post-antiviral revenue growth
- Hepatitis C revenues have declined dramatically from peak — this legacy revenue stream continues to shrink
- Humira biosimilar erosion is underway and will continue reducing the Humira revenue contribution over the next several years
- Skyrizi and Rinvoq face competition from new IL-23, IL-17, and JAK inhibitors from Novartis, UCB, and Lilly
- Botox aesthetics revenue is sensitive to consumer spending cycles and faces competition from biosimilar Botox (Jeuveau, Dysport)
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.